Online Testosterone Prescription. 2026 Comparison
Online TRT now covers the full delivery-route spectrum: injectable cypionate or enanthate (the gold-standard for serum trough control), transdermal cream or gel, subcutaneous pellets, sublingual troche, and oral options like KYZATREX or Jatenzo. The choice between routes is the single biggest decision in TRT and affects everything from labs to costs to what your insurance covers. Below: route comparison, lab requirements, the enclomiphene alternative for men who want fertility preservation, and how the major TRT-focused telehealth platforms differ.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Testosterone replacement therapy (TRT) is the prescription of exogenous testosterone for men with clinically confirmed hypogonadism (total T <300 ng/dL on at least two morning draws, with supportive symptoms). Per the 2018 Endocrine Society and 2024 AUA guidelines, TRT is appropriate only for documented hypogonadism, not for low-normal testosterone in symptomatic men, and not as a performance-enhancement protocol.
Men with documented hypogonadism (total testosterone <300 ng/dL on two morning draws, plus supportive symptoms: low libido, erectile dysfunction, fatigue, decreased muscle mass, mood changes). Best fit for men over 40 with primary or secondary hypogonadism. Not appropriate for men trying to conceive (suppresses spermatogenesis. use enclomiphene instead). Caution in men with prostate cancer history, severe sleep apnea, polycythemia, or severe heart failure. Not appropriate as a recreational or performance-enhancement protocol.
Most providers require pre-treatment labs: total + free testosterone (two morning draws), CBC, CMP, lipid panel, HbA1c, PSA (men 40+), and prolactin. Follow-up labs at 8–12 weeks to confirm therapeutic levels (target 500–800 ng/dL) and screen for hematocrit elevation. Injectable testosterone cypionate (the most common): $30–$50/mo for the medication, $100–$200/mo all-in including consult and labs. Cream/gel: $80–$150/mo. Pellets: $400–$800 per insertion every 3–6 months. Oral KYZATREX/Jatenzo: $500–$700/mo. Most platforms require quarterly check-ins and annual labs as standard of care.
Verified Offers for online
Hone Health
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
MangoRx
Custom-compounded, rapid-dissolve treatments for men's health with transparent pricing and free provider visits.
Online doctor's office and pharmacy with 48-hour delivery and no required virtual visit in most states.
What the Studies Actually Show
Testosterone replacement therapy is FDA-approved for documented hypogonadism. The figures below come from the Endocrine Society and AUA clinical practice guidelines and from the FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Diagnostic threshold (Endocrine Society 2018)1 | Treatment is considered when total testosterone is consistently below ~264 ng/dL with consistent symptoms of hypogonadism |
| Cardiovascular safety (TRAVERSE, 5,246 men, ~33 months)2 | Testosterone replacement was non-inferior to placebo for major adverse cardiovascular events in middle-aged and older men with hypogonadism and elevated CV risk |
| Required safety monitoring (AUA 2018)3 | Hematocrit at baseline, 3–6 months, then annually; PSA at baseline and at follow-up testing in men age ≥40; lipids and CMP at baseline and 6–12 months |
| Hematocrit safety endpoint3 | Treatment paused if hematocrit exceeds 54% to reduce thrombotic risk |
| Fertility1 | Exogenous testosterone suppresses LH/FSH and spermatogenesis. Men interested in fertility should consider enclomiphene or hCG instead, or alongside, TRT |
Frequently Asked Questions
- Endocrine Society Guideline — J Clin Endocrinol Metab 2018 · Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103(5):1715–1744.
- TRAVERSE — NEJM 2023 · Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 2023;389:107–117.
- AUA Guideline — J Urol 2018 · Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018;200(2):423–432.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.